Processivity and drug-dependence of HIV-1 protease
- 1 March 2003
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (5) , 663-671
- https://doi.org/10.1097/00002030-200303280-00003
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacityAIDS, 2002
- Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutationsJournal of Medical Virology, 2001
- Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of DrugJournal of Virology, 2000
- Fitness of Human Immunodeficiency Virus Type 1 Protease Inhibitor-Selected Single MutantsVirology, 2000
- HIV drug resistance and viral fitnessPublished by Elsevier ,2000
- Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapyAIDS, 1999
- Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapyProceedings of the National Academy of Sciences, 1998
- Altered Drug Sensitivity, Fitness, and Evolution of Human Immunodeficiency Virus Type 1 withpolGene Mutations Conferring Multi‐Dideoxynucleoside ResistanceThe Journal of Infectious Diseases, 1998
- RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVALAnnual Review of Microbiology, 1997
- Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drugJournal of General Virology, 1996